Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.
Dimebon (latrepirdine) is supported by a number of research and clinical presentations and papers.PublicationsBachurin S, Bukatina E, et al. Antihistamine agent Dimebon as a novel neuroprotector and cognitive enhancer. Annals of the New York Academy of Sciences. 2001;939:425-435. Bachurin SO, Shevtsova EP, et al. Mitochondria as a target for neurotoxins and neuroprotective agents. Annals of the New York Academy of Sciences. 2003;993:334-344. Bukatina EE, Afanas’ev AZ, et al. Medicine for treatment of Alzheimer’s disease. Abstract presented at The 4th Congress of the European Society for Clinical Neuropharmacology. Doody RS, Gavrilova SI, et al. Effect of Dimebon on cognition, activities of daily living, behavior, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled study. The Lancet. 2008;372:207-15. Grigor'ev VV, Dranyi OA, Bachurin SO. Comparative study of action mechanisms of Dimebon and memantine on AMPA and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bulletin of Experimental Biology and Medicine. 2003;136(5):474-477. Kieburtz K, McDermott MP, et al. A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease. Archives of Neurology. 2010; 67(2): 154-160. Lermontova NN, Lukoyanov, NV, et al. Dimebon improves learning in animals with experimental Alzheimer’s disease. Bulletin of Experimental Biology and Medicine. 2000;129(6):640-642. Lermontova NN, Redkozubov AE, et al. Dimebon and tacrine inhibit neurotoxic action of β-amyloid in culture and block L-type Ca2+ channels. Bulletin of Experimental Biology and Medicine. 2001;5:1079-1083. Marsh JL, Pallos J, et al. Fly models of Huntington’s disease. Human Molecular Genetics 2003;12:R187-R193. Moreira PI, Xiongwei Z, et al. Mitochondria: a therapeutic target in neurodegeneration. Biochimica et biophysica acta. 2010;1802(1):212-20. |
 |
 |
| Medivation © 2010 |